Prophylactic Vaccines Archives - CureVac

Optimization of Non-Coding Regions for a Non-Modified mRNA COVID-19 Vaccine

by Barbara Koegel-Hubbuch

mRNA-Based Vaccines and Mode of Action

by Barbara Koegel-Hubbuch

RNA-based adjuvant CV8102 enhances the immunogenicity of a licensed rabies vaccine in a first-in-human trial

New Vaccine Technologies to Combat Outbreak Situations

Phase I dose-escalation and expansion study of intratumoral CV8102, a RNA-based TLR- and RIG-1 agonist in patients with advanced solid tumors

Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines

Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial

Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response

Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity

An mRNA Vaccine Encoding Rabies Virus Glycoprotein Induces Protection against Lethal Infection in Mice and Correlates of Protection in Adult and Newborn Pigs